Oluwasegun Eniayewu

Oluwasegun Eniayewu

Auto-generated profile, based on publicly available information

Oluwasegun Eniayewu

Department of Pharmaceutical Chemistry Faculty of Pharmacy, Obafemi Awolowo University Ile Ife Nigeria

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
SAShakir Atoyebi
Shakir Atoyebi
FBFazila Bunglawala
Fazila Bunglawala
NCNicolas Cottura
Nicolas Cottura
SGSandra Grañana‐Castillo
Sandra Grañana‐Castillo
MMMaiara Camotti Montanha
Maiara Camotti Montanha
CWCatriona Waitt
Catriona Waitt
Aims: Long‐acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use in pregnancy are limited. Physiologically‐based pharmacokinetic (PBPK) modelling was used to simulate the approved dosing regimens in pregnancy and explore if Ctrough was maintained above cabotegravir and rilpivirine target concentrations (664 and 50 ng/mL, respectively).Methods: An adult PBPK model was validated using clinical data of cabotegravir and rilpivirine in nonpregnant adults. This was modified by incorporating pregnancy‐induced metabolic and physiological changes. The pregnancy PBPK model was validated with data on oral rilpivirine and raltegravir (UGT1A1 probe substrate) in pregnancy. Twelve weeks' disposition of monthly and bimonthly dosing of long‐acting cabotegravir and rilpivirine was simulated at different trimesters and foetal exposure was also estimated.Results: Predicted Ctrough at week 12 for monthly long‐acting cabotegravir was above 664 ng/mL throughout pregnancy, but below the target in 0.5% of the pregnant population in the third trimester with bimonthly long‐acting cabotegravir. Predicted Ctrough at week 12 for monthly and bimonthly long‐acting rilpivirine was below 50 ng/mL in at least 40% and over 90% of the pregnant population, respectively, throughout pregnancy. Predicted medians (range) of cord‐to‐maternal blood ratios were 1.71 (range, 1.55‐1.79) for cabotegravir and 0.88 (0.78‐0.93) for rilpivirine between weeks 38 and 40.Conclusions: Model predictions suggest that monthly long‐acting cabotegravir could maintain antiviral efficacy throughout pregnancy, but that bimonthly administration may require careful clinical evaluation. Both monthly and bimonthly long‐acting rilpivirine may not adequately maintain antiviral efficacy in pregnancy.

28 November 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
OBOlasunkanmi David Bamidele
Olasunkanmi David Bamidele
BKBlessing Ayomide Kayode
Blessing Ayomide Kayode
OEOluwasegun Ibrahim Eniayewu
Oluwasegun Ibrahim Eniayewu
AAAdebanjo Adegbola
Adebanjo Adegbola
RORaphael Segun Olatoye
Raphael Segun Olatoye
MBMoji Taibat Bakare-Odunola
Moji Taibat Bakare-Odunola
Hydroquinone, Mercury (Hg), and Arsenic (As) are hazardous to health upon long-term exposure. Hydroquinone, Hg, and As were analysed in skin-lightening cosmetics randomly purchased from different cosmetic outlets within the Ilorin metropolis, Nigeria. The amount of hydroquinone in the samples was determined using a UV-spectrophotometry method at 290 nm. Hg and As were quantified using atomic absorption spectrophotometry (AAS). UV-spectrophotometry method validation showed excellent linearity (r2 = 0.9993), with limits of detection (0.75 µg/mL), limits of quantification (2.28 µg/mL), relative standard deviation (0.01–0.35%), and recovery (95.85–103.56%) in the concentration range of 5–50 µg/mL. Similarly, r2, LOD, and LOQ for Hg and As were 0.9983 and 0.9991, (0.5 and 1.0 µg/L) and 1.65 and 3.3 µg/L) respectively. All the samples contained hydroquinone, Hg and As in varying amounts. The amounts of hydroquinone, Hg and As present were in the ranges of 1.9–3.3%, 0.08–2.52 µg/g and 0.07–5.30 µg/g respectively. Only three of the analysed samples contained hydroquinone within the permissible limit of 2.0% w/w in cosmetic products. All the samples analysed contained mercury and arsenic in varying amounts. The need to periodically monitor the levels of hydroquinone, mercury, and arsenic in skin-lightening cosmetics marketed in Nigeria is recommended.

10 June 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
OEOluwasegun Eniayewu
Oluwasegun Eniayewu
UAUche Azuka
Uche Azuka
JOJonah Ogah
Jonah Ogah
EAEbunoluwa Adejuyigbe
Ebunoluwa Adejuyigbe
OBOluseye Bolaji
Oluseye Bolaji
AOAdeniyi Olagunju
Adeniyi Olagunju
In this study, we investigated the combined influence of pregnancy and genetic polymorphisms on efavirenz pharmacokinetics in cervicovaginal fluid (CVF) of women receiving antiretroviral therapy. Women receiving efavirenz‐containing antiretroviral therapy were recruited from two hospitals in Nigeria during 2017–2020. Sparse CVF and plasma samples were obtained during pregnancy to assess the possible association between drug concentration and CYP2B6 polymorphisms (stage I). Participants were stratified into three CYP2B6 516G>T (rs3745274) genotype groups and re‐enrolled for intensive pharmacokinetic sampling (stage II). Overall, 159 women (142 pregnant and 12 postpartum) contributed samples in stage I (88 CVF, 81 plasma and 73 paired). CYP2B6 516G>T (rs3745274) remained independently associated with log10 efavirenz CVF concentration during pregnancy after adjusting for plasma concentration, with β (Log10 efavirenz concentration, 95%CI) of 0.204 (0.027, 0.382), P = 0.025). Median (IQR) efavirenz C min in CVF during pregnancy (n = 12) vs. postpartum (n = 12) was 243 ng/mL (168–402) vs. 447 ng/mL (159–974), C max was 1,031 ng/mL (595–1,771) vs. 1,618 ng/mL (675–2,695), and AUC0‐24h was 16,465 ng.h/mL (9,356–30,417) vs. 30,715 ng.h/mL (10,980–43,714). CVF‐to‐plasma AUC ratio was 0.36 during pregnancy and 0.46 postpartum. Upon stratification, efavirenz clearance during pregnancy was 57.9% higher than postpartum in patients with the CYP2B6 516GT genotype; the AUC0‐24h and C max were 33.8% and 8.6% lower, respectively. Efavirenz C min in CVF exceeded the protein binding‐adjusted IC90 (PBIC90) of 126 ng/mL during pregnancy and postpartum. Efavirenz is well distributed into the CVF; both pregnancy and CYP2B6 polymorphisms affect the extent of exposure.

1 February 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
SAShakir Atoyebi
Shakir Atoyebi
PVPrajith Venkatasubramanian
Prajith Venkatasubramanian
AAAbdulafeez Akinloye
Abdulafeez Akinloye
OEOluwasegun Eniayewu
Oluwasegun Eniayewu
BBBrookie M. Best
Brookie M. Best
AOAdeniyi Olagunju
Adeniyi Olagunju
Model‐informed drug development is increasingly integrated across the drug development continuum, enabling more efficient, cost‐effective, and targeted trials while reducing reliance on animal studies. Achieving pharmacoequity requires not only equitable access to medicines but also to the data and knowledge that inform drug development and regulatory decisions. To address challenges in pharmacokinetic data sharing, PKRxiv ( https://pkrxiv.org/ ) was developed as a discipline‐specific repository designed around Findable, Accessible, Interoperable, Reusable (FAIR) principles. This tutorial introduces PKRxiv’s rationale, design, data submission and access workflows, and practical use cases. Available datasets at the end of September 2025 include over 5,500 individual drug concentration‐time data points from over 900 unique participants across 3 continents. The platform supports structured submission of pharmacokinetic, pharmacogenetic, and safety/efficacy data, with persistent digital object identifiers for discoverability and citation. Contributors can apply one of three data sharing models—unrestricted, noncommercial, or contributor‐controlled—with optional embargo periods. Users can explore datasets using the Data Explorer or Data Cards, or submit requests after providing a statement of intended use case. It enables pooling of datasets across multiple studies. Recommendations to help advance the field are proposed as data sharing becomes more widely expected: obtaining consent for unspecified future research use of data, sharing data underlying peer‐reviewed publications as standard practice, including discipline‐specific repositories in data management plans, and incentivizing post‐approval data sharing by industry. Supporting data from all therapeutic areas and population groups, PKRxiv is a critical step toward a more transparent, equitable, and collaborative future in clinical pharmacology research.

31 January 2024
Verified
Preprint
Open access
AOAdeniyi Olagunju
Adeniyi Olagunju
JNJacinta Nwogu
Jacinta Nwogu
OEOluwasegun Eniayewu
Oluwasegun Eniayewu
SAShakir Atoyebi
Shakir Atoyebi
AAAlieu Amara
Alieu Amara
SKSaye Khoo
Saye Khoo
Aim: An LC-MS/MS method to quantify drug in dried cervicovaginal secretions from flocked swab was developed and validated using the antiretroviral efavirenz as example. Methods: Cervicovaginal swabs (CVS) were prepared by submerging flocked swabs in efavirenz-spiked matrix. Time to full saturation, weight uniformity, recovery and room temperature stability were evaluated. Chromatographic separation was on a reverse-phase C18 column by gradient elution using 1mM ammonium acetate in water/acetonitrile at 400 µL/min. Detection and quantification were on a TSQ Quantum Access triple quadrupole mass spectrometer operated in negative ionisation mode. The method was used to quantify efavirenz in CVS samples from HIV-positive women in the VADICT study (NCT03284645). Results: Swabs were fully saturated within 15 seconds, absorbing 128 µL of matrix with coefficient of variation (%CV) below 1.3%. The method was linear with a weighting factor (1/X) in the range of 25-10000 ng/mL with inter- and intra-day precision (% CV) of 7.69-14.9%, and accuracy (% bias) of 99.1-105.3%. Mean recovery of efavirenz from CVS was 83.8% (%CV, 11.2) with no significant matrix effect. Efavirenz remained stable in swabs for at least 35 days after drying and storage at room temperature. Median (range) CVS efavirenz AUC0-24h was 16370 ng*h/mL (5803-22088), Cmax was 1618 ng/mL (610-2438) at a Tmax of 8.0 h (8.0-12), and Cmin was 399 ng/mL (110-981). Efavirenz CVS:plasma AUC0-24 ratio was 0.41 (0.20-0.59). Conclusion: Further application of this method will improve our understanding of the pharmacology of other therapeutics in the female genital tract, including in low- and middle-income countries.

5 December 2018 in Journal of Pharmacy & Bioresources
Verified
Journal Article
Closed access
PDF file
MBMoji T. Bakare-Odunola
Moji T. Bakare-Odunola
NNNgaitad S. Njinga
Ngaitad S. Njinga
RARashidat O. Ayanniyi
Rashidat O. Ayanniyi
MBMunirat K. Bello
Munirat K. Bello
SASa’ad T. Abdullahi
Sa’ad T. Abdullahi
HBHadiyah R. Bello
Hadiyah R. Bello
Phytochemical, elemental, antioxidant, antimicrobial and hypoglycemic studies of a mixed herbal product used for the management of diabetics